Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers

By LabMedica International staff writers
Posted on 25 Jul 2026

Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. More...

Core laboratories also face pressure to expand access and maintain throughput using existing analyzers. Capillary collection offers a patient-friendly alternative but lacks on‑label validation across many routine assays in centralized labs. Siemens Healthineers now introduces CE‑marked capillary testing claims for 24 assays on its Atellica analyzers.

Siemens Healthineers has launched capillary testing on the Atellica CH, IM, and CI Analyzers after receiving CE‑mark for 24 capillary blood testing claims, an advancement intended to provide greater confidence in results and higher throughput. The CE‑marked capillary claims are validated to run on the Atellica analyzers. The offering is designed to help core laboratories scale testing using existing infrastructure.

Capillary blood testing is collected via finger prick or heel stick instead of venipuncture. The Atellica menu supports common laboratory testing needs, including assays that comprise the comprehensive metabolic panel, lipid panels, thyroid function, Vitamin D, and HbA1c. This approach is positioned to offer flexibility for diverse patient testing needs.

According to the company, capillary claims provide on‑label, validated performance data that has not been standard practice on core laboratory analyzers. Laboratories previously offering capillary testing have typically undertaken additional steps to validate performance because collection methods can influence quality and accuracy. Many labs have therefore remained dependent on venous draws even as patient access challenges, staffing shortages, and the demand for faster turnaround times have grown.

In the United States, Siemens Healthineers offers four assays with capillary claims: total protein (TP_2), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and triiodothyronine (T3). The company is pursuing additional capillary testing claims with the U.S. Food and Drug Administration (FDA), subject to regulatory review. The broader set of 24 CE‑marked capillary claims is not available for sale in the United States, and future availability cannot be guaranteed.

“Offering a capillary test menu expands the testing that can be done in the core lab to reach more patients and support more testing needs – all with the same systems they already trust,” said Sharon Bracken, head of Diagnostics, Siemens Healthineers. “Our efforts to expand capillary claims across our assay menu build upon our broader vision to make testing more accessible, efficient, and patient-friendly.” 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.